Zoe Adjei

Zoe Adjei

Auto-generated profile, based on publicly available information

Zoe Adjei

PGY-2 Ambulatory Pharmacy Resident, Department of Pharmacy, University of Cincinnati Health, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Journal of International Medical Research
Verified
Journal Article
Open access
MBMarisa B. Brizzi
Marisa B. Brizzi
TCTracy L. Cable
Tracy L. Cable
DPDimple C. Patel
Dimple C. Patel
KWKelli Williams
Kelli Williams
ZAZoe Adjei
Zoe Adjei
CFCarl J. Fichtenbaum
Carl J. Fichtenbaum
Antiretroviral (ARV) drug resistance poses a threat to ending the HIV epidemic. As the rates of integrase resistance continue to increase globally, the availability of options for HIV treatment becomes limited. Heavily treatment-experienced (HTE) people with HIV (PWH) are limited to two or fewer available fully active ARV classes and are more likely to have an AIDS-defining event. Appropriate identification and management of HTE PWH is crucial to improving patient outcomes and reducing the future spread of drug-resistant HIV. As treatment options become more limited owing to drug resistance, the availability of more potent drugs with a marked increase in virologic suppression is needed in the current ART era. The purpose of this narrative review is to review the identification of HTE PWH, novel mechanisms of resistance, and management of HTE PWH in resource-rich and resource-limited settings using novel ARVs and combination ART.